Market news

It was the subject of a recommendation upgrade from an analyst.

STAAR Surgical (STAA) shares rose 7% in Tuesday trading after Stifel upgraded the stock to buy from

Stifel upgraded STAAR Surgical to Buy, while raising its price target, citing China momentum, EVO+ mix and upside to 2026-27 estimates.

Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.

STAAR Surgical (STAA) stock gains as Stifel upgrades the company to Buy, citing a compelling entry point and H2 2026 sales upside—especially in China. Read more here.

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 6.3% in the afternoon session after the company announced that its board of directors authorized a share repurchase program of up to $50 million.

It has launched a $50 million share repurchase program.

It has launched a $50 million share repurchase program.

(Updates with stock movement in first paragraph and headline.) STAAR Surgical (STAA) shares rose

STAAR Surgical (STAA) said Thursday its board approved a share repurchase program allowing the compa

LAKE FOREST, Calif., September 24, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock.

STAAR Surgical recently reported quarterly net sales of US$93.5 million, an increase of 111% year over year, driven largely by China where revenue more than doubled to US$52.3 million and helped swing the company to US$8.1 million in net income from a loss a year earlier. Alongside this earnings rebound, STAAR strengthened its leadership bench by appointing former CEO David Bailey as Chief Commercial Officer and Ben Park, Ph.D., as Chief Technology Officer, signaling a focus on accelerating...

Executive Changes Reframe STAAR Surgical After Turnaround Results STAAR Surgical (STAA) reported a sharp business turnaround, with net sales rising 111% year over year and net income reaching $8.1 million, helped by China now contributing more than half of revenue. That backdrop sets the stage for two fresh executive appointments at the ophthalmic device producer. These moves could shape how the recent performance is translated into longer term commercial and product decisions. On the market...

On August 12, STAAR Surgical (NASDAQ:STAA) reported results for the quarter ended July 3 that flipped the script from a year earlier. Net sales jumped 111% year over year to $93.5 million, and the company that lost money in the same quarter of 2025 turned in $8.1 million of net income instead. It is the […]

David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company.

Detailed price information for Staar Surgical Company (STAA-Q) from The Globe and Mail including charting and trades.

LAKE FOREST, Calif., September 10, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market.

LAKE FOREST, Calif., September 09, 2026--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer.

STAAR Surgical (STAA) said late Tuesday it named David Bailey as chief commercial officer. Bailey

STAAR Surgical (STAA) appointed Ben Park as chief technology officer. Park most recently served a

Detailed price information for Azz Inc (AZZ-N) from The Globe and Mail including charting and trades.

Check out the companies making headlines this week:

Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.

STAAR Surgical’s second quarter results surpassed Wall Street’s expectations for both revenue and adjusted earnings, but the market reacted negatively, likely reflecting investor caution about the sustainability of recent growth. Management attributed the strong quarter to increased adoption of EVO Plus in China, ongoing market share gains from laser-based competitors, and consistent double-digit growth outside China, especially in the U.S. and EMEA. CEO Warren Foust emphasized that the company’

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) fell 8.3% in the afternoon session after sentiment faded following its underwhelming second quarter earnings reported the previous week.

Detailed price information for Staar Surgical Company (STAA-Q) from The Globe and Mail including charting and trades.

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

STAAR Surgical (STAA) is back in focus after its latest earnings showed sales of US$93.54 million for the second quarter and net income of US$8.06 million, compared with a loss in the prior year. See our latest analysis for STAAR Surgical. The latest results and August leadership changes have pulled STAAR Surgical back into focus. The recent 1-day share price return of 3.36% and 7-day return of 8.14% contrast with a 90-day share price decline of 18.97% and a 5-year total shareholder return...

STAAR Surgical reported past second-quarter 2026 results showing sales of US$93.54 million versus US$44.32 million a year earlier, with net income of US$8.06 million replacing a net loss of US$16.81 million and earnings per share improving to US$0.16 from a US$0.34 loss. Alongside these results, the board’s recent move to appoint long-time operator Warren Foust as CEO underscores how leadership changes and an operational reset have coincided with the company’s shift back to...

STAAR Surgical (NasdaqGM: STAA) has appointed Warren Foust as permanent President and CEO and added him to the board of directors. The decision follows a period of operational reset at the company and a reported return to profitable growth under Foust's leadership. The move replaces the prior temporary co-CEO structure and signals a defined leadership direction for the ophthalmic device maker. For investors watching how leadership quality shapes execution in specialized medical technology,...

STAAR Surgical stock is coming into focus again as investors weigh a sharp share price decline over the past five years against mixed valuation signals, with one key intrinsic value estimate pointing to some upside while market based multiples suggest the shares are not cheap. STAAR Surgical shares have delivered a decline of 79.8% over the past five years, which raises questions about how much of the business risk and execution uncertainty is already reflected in the price. Expectations for...

Medical lens company STAAR Surgical (NASDAQ:STAA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 111% year on year to $93.54 million. Its non-GAAP profit of $0.25 per share was 9.7% above analysts’ consensus estimates.

STAAR Surgical (STAA) has an average rating of hold and mean price target of $28.78, according to an

Moby summary of STAAR Surgical Company's Q2 2026 earnings call

STAAR Surgical (STAA) has an average rating of hold and mean price target of $28.89, according to an

Detailed price information for Staar Surgical Company (STAA-Q) from The Globe and Mail including charting and trades.

STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company’s strongest first half of re